Streetbeat News

Analyst Ratings

JNJ

Morgan Stanley analyst Terence Flynn has maintained an Equal-Weight rating on Johnson & Johnson (NYSE:JNJ) and raised the price target from $183 to $187.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:26 pm

JAZZ

Morgan Stanley analyst Jeffrey Hung has reiterated an Equal-Weight rating on Jazz Pharmaceuticals and maintained a price target of $187.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:23 pm

IRTC

Morgan Stanley analyst Cecilia Furlong has reiterated an Overweight rating on iRhythm Technologies (NASDAQ:IRTC), maintaining a price target of $149.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:22 pm

BLFS

Craig-Hallum analyst Matt Hewitt has initiated coverage on BioLife Solns (NASDAQ:BLFS) with a Buy rating and a price target of $29.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:19 pm

WULF

Northland Capital Markets has initiated coverage on TeraWulf (NASDAQ:WULF) with an Outperform rating and a price target of $4.25.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:18 pm

ITCI

Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:18 pm

C

CRBG

Citigroup analyst Michael Ward has reinstated Corebridge Financial (NYSE:CRBG) with a Neutral rating and announced a $19 price target.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:17 pm

GWW

J

V

On CNBC's 'Halftime Report Final Trades', Bryn Talkington of Requisite Capital Management named Visa Inc. as a potential bright spot in the financial sector, with the company due to report earnings growth of around 6.6% and revenue growth of 10.8%. Stephen Weiss of Short Hills Capital Partners mentioned Jacobs Solutions Inc., which recently inked an Engineering Partnering Agreement with Fortescue Future Industries. Joseph Terranova of Virtus Investment Partners picked W.W. Grainger, Inc., which reported better-than-expected earnings for its first quarter.

Portfolio Pulse from Lisa Levin

July 11, 2023 | 1:17 pm

IMCR

Morgan Stanley analyst Andrew Galler has reiterated an Overweight rating on Immunocore Hldgs (NASDAQ:IMCR) and maintained a $79 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:16 pm

GILD

Morgan Stanley analyst Matthew Harrison has reiterated an Equal-Weight rating on Gilead Sciences (NASDAQ:GILD) and maintained a price target of $86.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:14 pm